Dopamine uptake blockers protect against the dopamine depleting effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse striatum

G. A. Ricaurte, J. W. Langston, L. E. DeLanney, I. Irwin, J. D. Brooks

Research output: Contribution to journalArticlepeer-review

Abstract

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a recently described neurotoxin, produces a marked dopamine (DA) depletion in the mouse striatum. In this study, a series of DA uptake blockers was tested for their ability to prevent this effect of MPTP. The agents tested (amfonelic acid, benztropine, bupropion and mazindol) completely protected against DA depletion in the mouse striatum when given before DA-depleting doses of MPTP were administered, whereas atropine and trihexyphenidyl (which were employed for comparative purposes) did not. DA uptake blocking agents appear to represent a second general class of compounds, monoamine oxidase inhibitors being the first, which protect against the biologic effects of MPTP in the mouse.

Original languageEnglish (US)
Pages (from-to)259-264
Number of pages6
JournalNeuroscience Letters
Volume59
Issue number3
DOIs
StatePublished - Sep 6 1985
Externally publishedYes

Keywords

  • 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
  • Parkinson's disease
  • dopamine
  • mouse
  • neostriatum
  • neurotoxicity
  • substantia nigra

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Dopamine uptake blockers protect against the dopamine depleting effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse striatum'. Together they form a unique fingerprint.

Cite this